Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| STIM | Neuronetics, Inc. | 2025-12-02 08:00:15 | 1.39 | -0.03 | -2.11 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STIM | 0001227636 | Neuronetics, Inc. | US64131A1051 | 549300T0911ILTTG7P06 | — | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 3222 PHOENIXVILLE PIKE | MALVERN | PA | 19355 | UNITED STATES | US | 877-600-7555 | 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355 | 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355 | NEURONETICS INC | — | 2003 | Keith J. Sullivan | 167 | https://neurostar.com/ | 48,900,000 | 68,445,000 | 68,485,922 | Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. | 2025-11-27 19:21:52 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 48,900,000 | -7,600,000 | -13.4513 | 65,814,512 | 36,058,459 | 121.1802 |
| 2023 | 56,500,000 | -11,200,000 | -16.5436 | 29,756,053 | 1,392,633 | 4.91 |
| 2022 | 67,700,000 | -328,500,000 | -82.9127 | 28,363,420 | 1,735,614 | 6.5181 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| W. Andrew Macan | Chief Compliance Officer, Corporate Secretary, Executive Vice President, General Counsel | 2024 | 450,000 | 45,000 | 512,213 | 52,313 | 0 | 1,059,526 |
| Stephen Furlong | Chief Financial Officer, Executive Vice President | 2024 | 466,100 | 46,610 | 546,000 | 54,184 | 69,285 | 1,182,179 |
| Keith J. Sullivan | Chief Executive Officer, President | 2024 | 728,000 | 0 | 1,503,000 | 169,260 | 30,350 | 2,430,610 |
| Keith J. Sullivan | Chief Executive Officer, President | 2023 | 700,000 | 0 | 1,601,700 | 660,800 | 28,485 | 2,990,985 |
| W. Andrew Macan | Chief Compliance Officer, Corporate Secretary, Executive Vice President, General Counsel | 2023 | 409,400 | 51,175 | 531,000 | 155,572 | 13,556 | 1,160,703 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 716 |
| 2023 | 203 |
| 2022 | 195 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 74,890,000 | 71,348,000 | 65,206,000 |
| Cost Of Revenue | 20,729,000 | 19,643,000 | 15,483,000 |
| Gross Profit | 54,161,000 | 51,705,000 | 49,723,000 |
| Research And Development Expenses | 12,771,000 | 9,515,000 | 9,336,000 |
| General And Administrative Expenses | 30,322,000 | 25,426,000 | 25,516,000 |
| Operating Expenses | 88,724,000 | 82,259,000 | 84,834,000 |
| Operating Income | -34,563,000 | -30,554,000 | -35,111,000 |
| Net Income | -43,708,000 | -30,189,000 | -37,159,000 |
| Earnings Per Share Basic | -1.38 | -1.05 | -1.38 |
| Earnings Per Share Diluted | -1.38 | -1.05 | -1.38 |
| Weighted Average Shares Outstanding Basic | 31,734,000 | 28,658,000 | 26,900,000 |
| Weighted Average Shares Outstanding Diluted | 31,734,000 | 28,658,000 | 26,900,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 18,459,000 | 59,677,000 | 70,340,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 23,355,000 | 15,782,000 | 13,591,000 |
| Inventories | 4,248,000 | 8,093,000 | 8,899,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 3,078,000 | 2,514,000 | 1,997,000 |
| Total Assets Current | 58,122,000 | 93,793,000 | 98,769,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 6,242,000 | 2,009,000 | 1,991,000 |
| Other Assets Non Current | 1,923,000 | 4,430,000 | 3,645,000 |
| Total Assets Non Current | 82,781,000 | 22,038,000 | 18,115,000 |
| Total Assets | 140,903,000 | 115,831,000 | 116,884,000 |
| Accounts Payable | 11,077,000 | 4,752,000 | 2,433,000 |
| Deferred Revenue | 974,000 | 1,620,000 | 1,980,000 |
| Short Term Debt | — | — | 13,125,000 |
| Other Liabilities Current | 605,000 | 1,053,000 | 800,000 |
| Total Liabilities Current | 31,265,000 | 19,812,000 | 33,199,000 |
| Long Term Debt | 55,151,000 | 59,283,000 | 35,954,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 77,839,000 | 61,829,000 | 26,625,000 |
| Total Liabilities | 109,104,000 | 81,641,000 | 59,824,000 |
| Common Stock | 557,000 | 291,000 | 273,000 |
| Retained Earnings | -419,789,000 | -376,081,000 | -345,892,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 27,706,000 | 34,190,000 | 57,060,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,100,000 | 2,000,000 | 1,600,000 |
| Share Based Compensation Expense | 5,602,000 | 7,319,000 | 8,746,000 |
| Other Non Cash Income Expense | -28,000 | — | — |
| Change In Accounts Receivable | 3,727,000 | 8,831,000 | 6,317,000 |
| Change In Inventories | -3,150,000 | 1,098,000 | 2,587,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -1,985,000 | 2,029,000 | -1,968,000 |
| Change In Other Liabilities | -66,000 | -2,243,000 | 6,604,000 |
| Cash From Operating Activities | -30,997,000 | -32,038,000 | -30,739,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,466,000 | 2,369,000 | 3,269,000 |
| Acquisition Of Business | 2,553,000 | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -2,413,000 | -1,322,000 | 6,731,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 57,479,000 | 25,000,000 | — |
| Repayment Of Long Term Debt | 60,000,000 | 1,200,000 | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -6,808,000 | 22,697,000 | 207,000 |
| Change In Cash | -40,218,000 | -10,663,000 | -23,801,000 |
| Cash At End Of Period | 18,459,000 | 59,677,000 | 70,340,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 6,513,000 | 4,790,000 | 3,543,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.38 | -1.05 | -1.38 |
| Price To Earnings Ratio | -1.1667 | -2.7619 | -4.9783 |
| Earnings Growth Rate | 31.4286 | -23.913 | 13.1148 |
| Price Earnings To Growth Ratio | -0.0371 | 0.1155 | -0.3796 |
| Book Value Per Share | 1.002 | 1.193 | 2.1212 |
| Price To Book Ratio | 1.6067 | 2.4308 | 3.2387 |
| Ebitda | -34,322,000 | -22,765,000 | -31,308,000 |
| Enterprise Value | 87,783,740 | 82,714,200 | 163,542,000 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 1.9906 | 1.7339 | 0.8601 |
| Capital Expenditures | 6,333,000 | 2,018,000 | 2,371,000 |
| Free Cash Flow | -37,330,000 | -34,056,000 | -33,110,000 |
| Return On Equity | -1.5776 | -0.883 | -0.6512 |
| One Year Beta | 1.2471 | 1.3207 | 1.234 |
| Three Year Beta | 1.2372 | 1.2517 | 1.3089 |
| Five Year Beta | 1.3038 | 1.2956 | 1.259 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Cucuz Sasha | Director | 2025-10-20 | 6,410 | A | 1,512,798 |
| MUIR GLENN P | Director | 2025-10-20 | 7,554 | A | 371,816 |
| CONLEY SHERYL L | Director | 2025-10-20 | 7,326 | A | 221,716 |
| CASCELLA ROBERT | Director | 2025-10-20 | 10,531 | A | 588,767 |
| Madryn Asset Management, LP | 10% owner | 2025-08-08 | 192,806 | D | 1,142,351 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | 2025-09-30 | 40,147 | 14,706 | 2.73 |
| CIBC Private Wealth Group LLC | 2025-09-30 | 55 | 20 | 2.75 |
| Caitong International Asset Management Co., Ltd | 2025-09-30 | 6,882 | 2,521 | 2.7299 |
| RAYMOND JAMES FINANCIAL INC | 2025-09-30 | 65,967 | 24,164 | 2.73 |
| GOLDMAN SACHS GROUP INC | 2025-09-30 | 605,806 | 221,907 | 2.73 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| RYDEX SERIES FUNDS | 2025-09-30 | Class C | RYCMX | 51 | 139.23 | 0.0021 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class A | RYAKX | 51 | 139.23 | 0.0021 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class H | RYMKX | 51 | 139.23 | 0.0021 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class H | RYRHX | 85 | 232.05 | 0.0019 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class C | RYROX | 85 | 232.05 | 0.0019 |